Bravelle and Menopur both are the accepted prescriptions to cure infertility. BRAVELLE® is a highly purified preparation of human FSH which is Follicle Stimulating Hormone, containing 75 IUs FSH with 2% luteinizing hormone (LH) activity. The FSH and LH hormones are generated by anterior pituitary gland. FSH is substantial for developing eggs produced in ovaries. BRAVELLE 75 IU stimulates eggs to develop in women whose ovaries are basically healthy but are unable to develop eggs. It is not to be used by women who suffer from ovarian failure.
BRAVELLE® is usually used along with human chorionic gonadotropin (hCG), and is manifested for ovulation induction and multiple follicular development, following pituitary suppression. In assisted reproductive technology (ART), BRAVELLE has intimated safety and efficacy across a range of patient ages and types that includes donor and high BMI patients. BRAVELLE® is available by prescription in 5mL vials containing BRAVELLE 75 IU FSH with accompanying diluent.
BRAVELLE 75 IU implemented SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously got pituitary suppression. BRAVELLE® also administered IM along with SC in conjunction with hCG, is indicated for ovulation induction in already received pituitary suppression patients.
Important Safety Information for BRAVELLE 75IU
Only physicians, who are completely familiar with infertility treatment, that include the various risks associated with multiple births and adverse reactions, should give advice to use BRAVELLE®. BRAVELLE®, like all gonadotropins, is a potent substance that can cause mild to severe adverse reactions, including OHSS (incidence 6.0%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE® 75 IU is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to urofollitropins, purified. BRAVELLE® should also be not used by women who are pregnant because it may cause fetal harm. There are limited human data on the effects of BRAVELLE® when administered during pregnancy. You can get the best BRAVELLE price at Make Me Fertile as we import our medications in bulk from registered pharmacies in Israel and European Union and pass on the savings to our customers.
Alternative Brand Name: Fostimon 75IU HP
Learn more about Reproductive Therapy: IVF